Fig. 3From: Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter studyChanges in mean hemoglobin levels (line graph with closed circles) following a switch from erythropoietin treatment in a patients not on dialysis, b patients on hemodialysis, and c patients on peritoneal dialysis. Bar graph represents mean dose of continuous erythropoietin receptor activator (CERA) administered; error bars represent ± 1 standard deviationBack to article page